Adial Pharmaceuticals
ADIL
20 hedge funds and large institutions have $488K invested in Adial Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
13% less funds holding
Funds holding: 23 → 20 (-3)
44% less capital invested
Capital invested by funds: $877K → $488K (-$389K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$2.89K |
| 2 |
Renaissance Technologies
New York
|
+$1.81K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$362 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$181 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.3K |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$9.11K |
| 3 |
BlackRock
New York
|
-$9.04K |
| 4 |
EWM
Empirical Wealth Management
Seattle,
Washington
|
-$8.75K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$8.13K |
ADIL Hedge Fund Activity: Q2 2023 in Review
20 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2023, worth a combined $488K — down 44% from $877K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ADIL and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Creative Planning, opening a new position worth an estimated $2.89K. The largest seller was Susquehanna International Group, cutting an estimated $12.3K.
- 20 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2023, down from 23 in Q1 2023.
- Funds reported $488K of Adial Pharmaceuticals stock for Q2 2023, down 44% quarter-over-quarter.
- 2 funds opened new Adial Pharmaceuticals positions in Q2 2023 and 5 closed out, a net change of -3 holders.
- The largest Adial Pharmaceuticals buyer in Q2 2023 was Creative Planning, an estimated $2.89K added.
- The largest Adial Pharmaceuticals seller in Q2 2023 was Susquehanna International Group, an estimated $12.3K sold.
Based on aggregated 13F filings for Q2 2023.